Search
Research
Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infantsPapua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.
Research
The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
News & Events
Vaccine trial aims to curb ‘superbug’Sarah Le Roi knows well how debilitating Clostridium difficile infection (CDI) can be. She was struck down with the 'superbug' while on holiday in the US.
News & Events
The Kids Research Institute Australia researchers finalists for 2016 Eureka PrizesThree Perth researchers from The Kids Research Institute Australia have today been named finalists for the 2016 Australian Museum Eureka Prizes.
News & Events
Perth scientist receives prestigious honourAn internationally recognised researcher at The Kids Research Institute Australia has been made a Fellow of the Australian Academy of Science
News & Events
Large-scale study uncovers a single major genetic risk factor for fatal parasitic diseaseResearch has identified a critical genetic risk factor for a potentially fatal parasitic disease that affects up to 400 thousand people a year, mostly children.
News & Events
Pneumonia rates improve in Aboriginal childrenNew research from The Kids for Child Health Research shows that the pneumococcal vaccine program has contributed to closing of the gap
Research
Characterization of invasive Group B Streptococcus isolates from Western Australian infants, 2004-2020Invasive Group B Streptococcus remains a leading cause of infant morbidity and mortality. Intrapartum antibiotic prophylaxis has been implemented in many countries with a reduction in early-onset disease, but an effective vaccine may further reduce the disease burden. Candidate vaccines targeting capsular polysaccharides and surface proteins are now in clinical trials.
Research
Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedulesIn Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.
Research
The Unintended Impact of COVID-19 Associated Non-Pharmaceutical Interventions on Paediatric Hospital Admissions: An Interrupted Time Series AnalysisCOVID-19 related non-pharmaceutical interventions (NPIs) disrupted global healthcare utilisation, with notable declines in infection related paediatric hospitalisations. We aimed to identify non-infectious paediatric conditions for which the incidence of hospital admissions increased during the introduction and alleviation of NPIs in 2020.